NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia

Treated AML patients often have measurable residual disease (MRD) due to persisting low-level clones. This study assessed whether residual post-treatment somatic mutations, detected by NGS, were significantly prognostic for subsequent clinical outcomes. AML patients (n = 128) underwent both pre-and...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yonghong, Solis-Ruiz, Jose, Yang, Fei, Long, Nicola, Tong, Carmen H., Lacbawan, Felicitas L., Racke, Frederick K., Press, Richard D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123056/
https://www.ncbi.nlm.nih.gov/pubmed/37088803
http://dx.doi.org/10.1038/s41408-023-00833-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123056/
https://www.ncbi.nlm.nih.gov/pubmed/37088803
http://dx.doi.org/10.1038/s41408-023-00833-7

Ejemplares similares